IL12-F_H_AB-GMcSF

IL12-F_H_AB-GMcSF is a **preclinical bifunctional cytokine fusion protein immunotherapy** reported by Sonnet BioTherapeutics. Based on the naming convention used across Sonnet's FHAB platform and company disclosures, it appears to comprise **interleukin-12 fused to Sonnet's fully human albumin-binding domain and granulocyte-macrophage colony-stimulating factor**, with the intent of extending half-life through albumin binding and concentrating cytokine activity in tumors while combining the **Th1 and NK-cell activating effects of IL-12** with the **myeloid and dendritic-cell stimulating effects of GM-CSF**. Publicly available information indicates that the construct was being evaluated in **single-dose and multi-dose preclinical in vivo efficacy, biomarker, and FACS studies** rather than clinical trials. No brand name, regulatory approval, or disease-specific clinical development program could be confirmed from the available sources.

Other names

IL12-FHAB-GMcSFIL-12-FHAB-GMcSFIL 12-FHAB-GMcSFIL12-F H AB-GMcSFIL-12-F H AB-GMcSFIL 12-F H AB-GMcSFinterleukin-12 albumin-binding fusion protein with GM-CSFinterleukin12 albumin-binding fusion protein with GM-CSFinterleukin 12 albumin-binding fusion protein with GM-CSF